Please enable Javascript
Conferences
Partners
Expert Interviews
Subscribe
Heme Today
Anemia
Deep Vein Thrombosis
Essential Thrombocythemia
Hemophilia
Immune Thrombocytopenic Purpura
Myelodysplastic Syndromes
Myelofibrosis
Myeloproliferative Neoplasms
PNH
Polycythemia Vera
Pulmonary Embolism
Sickle Cell Disease
Thrombocytopenia
Thrombophilia
Thrombosis
Thrombotic Thrombocytopenic Purpura
Venous Thromboembolism
von Willebrand Disease
Nephrology Times
Acute Kidney Injury
ADPKD
Anemia and Kidney Disease
Chronic Kidney Disease
COVID-19 and Kidney Disease
Diabetes and Hypertension
End-Stage Renal Disease
Gout
Hyperkalemia
IgAN
Kidney Transplantation
Metabolic Acidosis
Breast Cancers Today
HER2 Breast Cancer
HR Breast Cancer
Triple-Negative Breast Cancer
Genetics & Breast Cancer
Cardiology
Atherosclerotic Disease
Atrial Fibrillation
Heart Failure
Hypertension
Interventional Cardiology
Lipid Management
Practice Tips With Dr. Lichaa
Preventive Cardiology
Stroke
Oncology
Breast Cancer
Gynecologic Cancer
Head and Neck Cancer
Skin Cancer
Sleep
Urology
More
Diabetes
Ophthalmology
— Demodex Blepharitis
Neurology
Rheumatology
Gastroenterology
Pulmonology
Infectious Diseases
— HIV
Health and Wellness
Lupus
Future of Medicine
Orthopedics
Pharmacology
Career News
Wafik El-Deiry, MD, PhD, FACP
Articles by Wafik El-Deiry, MD, PhD, FACP
Utilizing TAS-102 and Regorafenib for Future Studies
Wafik El-Deiry, MD, PhD, FACP
Colorectal Cancer
|
March 13, 2025
Dr. El-Deiry expands on reducing ALDH1 expression in HT29 cells, and the benefits of targeting ERK1/2 and STAT3 activation.
View More
Regorafenib and TAS-102 for GI Cancers
Wafik El-Deiry, MD, PhD, FACP
Colorectal Cancer
|
March 13, 2025
Dr. Wafik El-Deiry of Brown University discusses his study on regorafenib with TAS-102 for colorectal cancer.
View More